Wire · opportunities
Oncolytics Biotech paper reports liver tumor immune shift
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 September 2026 · Fusion42 review
Oncolytics Biotech published preclinical findings showing that pelareorep increases immune activity markers in liver tumors, potentially making them more responsive to immune-based therapies such as checkpoint inhibitors. Although the results are preclinical and the company currently does not plan to pursue liver cancer as an indication, the data are driving business development discussions.
This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery, and 2 sources have reported it between 29 Sep 2026 and 30 Sep 2026.
◆ ◆ The Wire takeaway
You in immunotherapy need to engage with the emerging potential of pelareorep to convert liver tumors to immune-responsive types because this could open collaboration or licensing doors despite the drug not pursuing liver cancer directly.
◆ Coverage
2 sources · first reported 29 Sep 2026 · latest 30 Sep 2026
◆ Related on Wire
◆ Topics